Search

Displaying results 2091 - 2100 of 10000 in total
  1. Drug

    Homatropine

    go.drugbank.com/drugs/DB11181
    Approved

    use has not been approved by the FDA to be safe and effective. … It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions.

  2. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    for exon 53 skipping. … [A218186] Hence, viltolarsen is similar to another PMO, [eteplirsen], which gained FDA approval on September 19, 2016; however, [eteplirsen] is specific for exon 51 skipping while viltolarsen is specific

  3. Drug

    Thymidine

    go.drugbank.com/drugs/DB04485
    ApprovedInvestigational

    [A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … [A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the

  4. Target

    Nuclear factor NF-kappa-B

    go.drugbank.com/bio_entities/BE0004903
    TargetHumans

    The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity … The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity

    Synonyms: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  5. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. … By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV.

  6. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have … [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same

    Categories: MATE 2-K Inhibitors
  7. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    [L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention … approved for the treatment of achondroplasia in both regions.

    Categories: Drugs for Treatment of Bone Diseases
  8. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is … It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.

    Synonyms: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
  9. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    As of June 2025, the FDA approved an expanded indication for Mavyret, making it the first and only direct-acting antiviral therapy approved for the treatment of both acute and chronic HCV in patients aged … Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Lormetazepam

    go.drugbank.com/drugs/DB13872
    Approved

    Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia [L927]. … It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

    Synonyms: N-Methyllorazepam, (RS)-Lormetazepam